Gastric Acid-Related Diseases: Focus on Esomeprazole.
Esomeprazole (S-omeprazole) is a single optical enantiomer proton-pump inhibitor (PPI) approved for the management of gastro-oesophageal reflux disease, the prevention and treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAID) associated gastric ulcer disease, treatment of duodenal ulcer disease...
| Publicado en: | Clinical Medicine Insights: Therapeutics no. 2; pp. 439 - 453 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=70639035&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 70639035 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1179559X B3KY jtl: Clinical Medicine Insights: Therapeutics issn: 1179559X maglogo: Y pubinfo: dt: 2010 iid: 2 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 70639035 104989432 10.4137/CMT.S4500 70639035 ppf: 439 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Gastric Acid-Related Diseases: Focus on Esomeprazole. aug: au: Al-Judaibi, B. Chande, N. Dresser, G. K. Sultan, N. J. C. Gregor affil: Division of Gastroenterology, The University of Western Ontario, London, ON, Canada sug: ab: Esomeprazole (S-omeprazole) is a single optical enantiomer proton-pump inhibitor (PPI) approved for the management of gastro-oesophageal reflux disease, the prevention and treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAID) associated gastric ulcer disease, treatment of duodenal ulcer disease associated with Helicobacter pylori infection, and the treatment of Zollinger-Ellison syndrome. Esomeprazole has been shown to be safe and effective during pregnancy and was introduced to the market in 2001. PPI therapy may interact with clopidogrel by cytocrome 2C19. Clopidogrel is a prodrug which is partially activated by cytochrome 2C19 and esomeprazole is a competitive inhibitor of 2C19. Esomeprazole is more effective than other PPIs in controlling esophageal and gastric pH, but efficacy in symptom relief is less clear. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|